Identification of muscle necrosis in the mdx mouse model of Duchenne muscular dystrophy using three-dimensional optical coherence tomography

Journal of Biomedical Optics

Volumn 16, Issue 7, 2011, Pages

  Klyen, Blake R ^a   Shavlakadze, Thea ^a   Radley Crabb, Hannah G ^a   Grounds, Miranda D ^a   Sampson, David D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Duchenne muscular dystrophy; Evans blue dye; Mdx mouse; Necrotic lesion; Optical coherence tomography; Skeletal muscle; Small animal imaging; Three dimensional imaging

Indexed keywords

EVANS BLUE DYES; MDX MOUSE; MUSCULAR DYSTROPHY; NECROTIC LESION; SKELETAL MUSCLE; SMALL ANIMAL IMAGING; THREE DIMENSIONAL IMAGING;

DISEASES; HISTOLOGY; MAMMALS; MUSCLE; NEUROMUSCULAR REHABILITATION; PATHOLOGY; TOMOGRAPHY;

THREE DIMENSIONAL;

ANIMALIA;

COLORING AGENT; DIAGNOSTIC AGENT; EVANS BLUE;

ANIMAL; ARTICLE; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; EVALUATION; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; MOUSE; NECROSIS; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; SKELETAL MUSCLE; THREE DIMENSIONAL IMAGING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; COLORING AGENTS; DISEASE MODELS, ANIMAL; EVANS BLUE; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NECROSIS; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 80455137206     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.3598842     Document Type: Article

References (45)

1. K. Bushby, R. Finkel, D. J. Birnkrant, L. E. Case, P. R. Clemens, L. Cripe, A. Kaul, K. Kinnett, C. McDonald, S. Pandya, J. Poysky, F. Shapiro, J. Tomezsko, and C. Constantin, "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management," Lancet Neurol. 9(1), 77-93 (2010).
2. A. Y. Manzur and F. Muntoni, "Diagnosis and new treatments in muscular dystrophies," Postgrad. Med. J. 85(1009), 622-630 (2009).
3. E. Le Rumeur, S. J. Winder, and J.-F. Hubert, "Dystrophin: more than just the sum of its parts," BBA - Proteins Proteom. 1804(9), 1713-1722 (2010).
4. M. J. Spencer and J. G. Tidball, "Do immune cells promote the pathology of dystrophin-deficient myopathies?" Neuromuscular Disord. 11(6-7), 556-564 (2001). (Pubitemid 32761799)
5. J. G. Tidball and M. Wehling-Henricks, "Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis," Curr. Opin. Rheumatol. 17(6), 707-713 (2005). (Pubitemid 41546488)
6. N. P. Evans, S. A. Misyak, J. L. Robertson, J. Bassaganya-Riera, and R. W. Grange, "Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy," Am. J. Phys. Med. Rehabil. 88(6), 502-522 (2009).
7. T. Shavlakadze, J. White, J. F.Y. Hoh, N. Rosenthal, andM.D.Grounds, "Targeted expression of insulin-like growth factor-1 reduces early myofiber necrosis in dystrophic mdx mice," Mol. Ther. 10(5), 829-843 (2004). (Pubitemid 39419910)
8. M. D. Grounds and J. Torrisi, "Anti-TNFá (Remicade® ) therapy protects dystrophic skeletal muscle from necrosis," FASEB J. 18(6), 676-682 (2004). (Pubitemid 38451789)
9. S. Hodgetts,H.Radley, M. Davies, and M. D. Grounds, "Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNF á function with Etanercept in mdx mice," Neuromuscul. Disord. 16(9-10), 591-602 (2006). (Pubitemid 44374323)
10. S. Pierno, B. Nico, R. Burdi, A. Liantonio, M. P. Didonna, V. Cippone, B. Fraysse, J.-F. Rolland, D. Mangieri, F. Andreetta, P. Ferro, C. Camerino, A. Zallone, P. Confalonieri, and A. De Luca, "Role of tumour necrosis factor á, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach," Neuropathol. Appl. Neurobiol. 33(3), 344-359 (2007). (Pubitemid 46701042)
11. H. G. Radley, M. J. Davies, and M. D. Grounds, "Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment," Neuromuscul. Disord. 18(3), 227-238 (2008).
12. M. D. Grounds,H.G.Radley, G. S. Lynch, K. Nagaraju, and A. De Luca, "Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy," Neurobiol. Dis. 31(1), 1-19 (2008).
13. K. D.Wallace, J. N. Marsh, S. L. Baldwin, A. M. Connolly, R. Keeling, G. M. Lanza, S. A. Wickline, and M. S. Hughes, "Sensitive ultrasonic delineation of steroid treatment in living dystrophic mice with energy-based and entropy-based radio frequency signal processing," IEEE Trans. Ultrason. Ferroelectr. Freq. Control 54(11), 2291-2299 (2007). (Pubitemid 350249403)
14. D. Laux, H. Blasco, J. Y. Ferrandis, G. Hugon, G. Despaux, A. Leydier, and D.Mornet, "In vitro mousemodel in Duchenne muscular dystrophy diagnosis using 50-MHz ultrasound waves," Ultrasonics 50(8), 741- 743 (2010).
15. L. M. McIntosh, R. E. Baker, and J. E. Anderson, "Magnetic resonance imaging of regenerating and dystrophic mouse muscle," Biochem. Cell Biol. 76(2-3), 532-541 (1998). (Pubitemid 29102039)
16. L. M. McIntosh, K.-E. Granberg, K. M. Briere, and J. E. Anderson, "Nuclear magnetic resonance spectroscopy study of muscle growth, mdx dystrophy and glucocorticoid treatments: correlation with repair," NMR Biomed. 11(1), 1-10 (1998). (Pubitemid 28164843)
17. V. Straub, K. M. Donahue, V. Allamand, R. L. Davisson, Y. R. Kim, and K. P. Campbell, "Contrast agent-enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy," Magn. Reson. Med. 44(4), 655-659 (2000).
18. H. Amthor, T. Egelhof, I. McKinnell, M. E. Ladd, I. Janssen, J. Weber, H. Sinn, H.-H. Schrenk, M. Forsting, T. Voit, and V. Straub, "Albumin targeting of damaged muscle fibres in the mdx mouse can be monitored by MRI," Neuromuscul. Disord. 14(12), 791-796 (2004). (Pubitemid 39572399)
19. G.Walter, L. Cordier, D. Bloy, and H. L. Sweeney, "Noninvasive monitoring of gene correction in dystrophic muscle," Magn. Reson. Med. 54(6), 1369-1376 (2005). (Pubitemid 41740766)
20. M. Kobayashi, A. Nakamura, D. Hasegawa, M. Fujita, H. Orima, and S. Takeda, "Evaluation of dystrophic dog pathology by fatsuppressed T2-weighted imaging," Muscle Nerve 40(5), 815-826 (2009).
21. J. N. Kornegay, J. A. Li, J. R. Bogan, D. J. Bogan, C. L. Chen, H. Zheng, B. Wang, C. Qiao, J. F. Howard, and X. A. Xiao, "Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs," Mol. Ther. 18(8), 1501-1508 (2010).
22. M. Bartoli, N. Bourg, D. Stockholm, F. Raynaud, A. Delevacque, Y. Han, P. Borel, K. Seddik, N. Armande, and I. Richard, "A mouse model for monitoring calpain activity under physiological and pathological conditions," J. Biol. Chem. 281(51), 39672-39680 (2006). (Pubitemid 46041926)
23. S. V. Plotnikov, A. M. Kenny, S. J. Walsh, B. Zubrowski, C. Joseph, V. L. Scranton, G. A. Kuchel, D. Dauser,M. S. Xu, C. C. Pilbeam, D. J. Adams, R. P. Dougherty, P. J. Campagnola, and W. A. Mohler, "Measurement of muscle disease by quantitative second-harmonic generation imaging," J. Biomed. Opt. 13(4), 044018 (2008).
24. O. Friedrich, M. Both, C. Weber, S. Schurmann, M. D. H. Teichmann, F. von Wegner, R. H. A. Fink, M. Vogel, J. S. Chamberlain, and C. Garbe, "Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle," Biophys. J. 98(4), 606-616 (2010).
25. A. R. Baudy, A. Sali, S. Jordan, A. Kesari, H. K. Johnston, E. P. Hoffman, and K. Nagaraju, "Non-invasive optical imaging ofmuscle pathology in mdx mice using cathepsin caged near-infrared imaging," Mol. Imaging Biol. 13(3), 462-470 (2010).
26. J. J. Pasquesi, S. C. Schlachter, M. D. Boppart, E. Chaney, S. J. Kaufman, and S. A. Boppart, "In vivo detection of exercise-induced ultrastructural changes in genetically-altered murine skeletal muscle using polarization-sensitive optical coherence tomography," Opt. Express 14(4), 1547-1556 (2006). (Pubitemid 43270818)
27. B. R. Klyen, J. J. Armstrong, S. G. Adie, H. G. Radley,M. D. Grounds, and D. D. Sampson, "Three-dimensional optical coherence tomography of whole-muscle autografts as a precursor to morphological assessment of muscular dystrophy in mice," J. Biomed. Opt. 13(1), 011003 (2008).
28. L. F. B. Torres and L.W. Duchen, "Themutant mdx: Inherited myopathy in themouse. Morphological studies of nerves,muscles and end-plates," Brain 110(2), 269-299 (1987). (Pubitemid 17055813)
29. G. S. Sandhu, L. Solorio, A.-M. Broome, N. Salem, J. Kolthammer, T. Shah, C. Flask, and J. L. Duerk, "Whole animal imaging," Wires Syst. Biol. Med. 2(4), 398-421 (2010).
30. B. E. Bouma and G. J. Tearney, Eds., Handbook of Optical Coherence Tomography (Marcel Dekker, New York, 2002).
31. W. Drexler and J. G. Fujimoto, Eds., Optical Coherence Tomography: Technology and Applications (Springer, New York, 2008).
32. W. J. Hucker, C. M. Ripplinger, C. P. Fleming, V. V. Fedorov, A. M. Rollins, and I. R. Efimov, "Bimodal biophotonic imaging of the structure-function relationship in cardiac tissue," J. Biomed. Opt. 13(5), 054012 (2008).
33. H. G. Radley-Crabb, J. Terrill, T. Shavlakadze, J. Tonkin, P. G. Arthur, and M. D. Grounds, "A single 30 minute treadmill exercise session is suitable for 'proof-of concept studies' in adult mdx mice: a comparison of the early consequences of two different treadmill protocols," Neuromuscul. Disord. (under review).
34. J. Terrill, H. G. Radley-Crabb, M. D. Grounds, and P. G. Arthur, "Nacetylcysteine treatment of dystrophic mdx mice results in protein thiol modifications and inhibition of exercise induced myofibre necrosis," Neuromuscul. Disord. (under review).
35. P. W. Hamer, J. M. McGeachie, M. J. Davies, and M. D. Grounds, "Evans blue dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability," J. Anat. 200(1), 69-79 (2002). (Pubitemid 34285290)
36. A.V. Zvyagin, E. D. J. Smith, and D. D. Sampson, "Delay and dispersion characteristics of a frequency-domain optical delay line for scanning interferometry," J. Opt. Soc. Am. A 20(2), 333-341 (2003).
37. R. Matsuda, A. Nishikawa, and H. Tanaka, "Visualization of dystrophic muscle-fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle," J. Biochem. 118(5), 959-964 (1995).
38. C. P. Fleming, C. M. Ripplinger, B. Webb, I. R. Efimov, and A. M. Rollins, "Quantification of cardiac fiber orientation using optical coherence tomography," J. Biomed. Opt. 13(3), 030505 (2008).
39. D. L. Marks, E. J. Chaney, and S. A. Boppart, "Plastinated tissue samples as three-dimensional models for optical instrument characterization, " Opt. Express 16(20), 16272-16283 (2008).
40. R. A. McLaughlin, L. Scolaro, P. Robbins, C. Saunders, S. L. Jacques, and D. D. Sampson, "Parametric imaging of cancer with optical coherence tomography," J. Biomed. Opt. 15(4), 046029 (2010).
41. C. Y. Xu, J. M. Schmitt, S. G. Carlier, and R. Virmani, "Characterization of atherosclerosis plaques by measuring both backscattering and attenuation coefficients in optical coherence tomography," J. Biomed. Opt. 13(3), 034003 (2008).
42. F. J. van der Meer, D. J. Faber, J. Perree, G. Pasterkamp, D. B. Sassoon, and T. G. van Leeuwen, "Quantitative optical coherence tomography of arterial wall components," Lasers Med. Sci. 20(1), 45-51 (2005). (Pubitemid 41175884)
43. J. Bickenbach, R. Dembinski, M. Czaplik, S. Meissner, A. Tabuchi, M. Mertens, L. Knels, W. Schroeder, P. Pelosi, E. Koch, W. Kuebler, R. Rossaint, and R. Kuhlen, "Comparison of two in vivo microscopy techniques to visualize alveolar mechanics," J. Clin. Monit. Comput. 23(5), 323-332 (2009).
44. Y. Wu, J. Xi, L. Huo, P. Jason, E. J. Shin, S. A. Giday, A. M. Lennon, M. I. F. Canto, J. H. Hwang, and X. Li, "Robust high-resolution fine OCT needle for side-viewing interstitial tissue imaging," IEEE J. Sel. Top. Quantum Electron. 16(4), 863-869 (2010).
45. B. C. Quirk, R. A. McLaughlin, A. Curatolo, R. W. Kirk, P. B. Noble, and D. D. Sampson, "In situ imaging of lung alveoli with an optical coherence tomography needle probe," J. Biomed. Opt. 16(3), 036009 (2011).